Trial Profile
Phase II open-label study of M200 [volociximab] in patients with metastatic renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 May 2012
Price :
$35
*
At a glance
- Drugs Volociximab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 27 Dec 2007 Status change from ongoing to discontinued.
- 13 Aug 2007 Status changed from recruiting to in progress.
- 19 Sep 2005 New trial record.